Contemporary issues in the management of uncomplicated Type B aortic dissection: Early complications in medically treated patients.

Historically, management of uncomplicated Type B aortic dissection (uTBAD) involved impulse control via medical therapies. Recent advances in endovascular treatment modalities, such as thoracic endovascular aortic repair, have given way to a new paradigm for management, prompting contemporary randomized trials. However, studies evaluating early morbidity and failure of medical management in uTBAD remain sparse, as these patients frequently convert to complicated disease before trial enrollment, limiting societal recommendations and standardized treatment protocols. This focused, narrative review examines contemporary issues in the management of uTBAD, with emphasis on protocolized medical therapy, mechanisms, and predictors of early failure, and the clinical spectrum of progression to complicated TBAD. Evidence related to rupture, malperfusion syndromes, aneurysmal degeneration, dissection extension, effusions, and respiratory complications associated with medical management is summarized. Up to one-third of individuals initially classified as uTBADs develop early complications. Protocolized anti-impulse pathways improve efficiency, reduce length of stay, and lower costs but do not eliminate progression to complicated disease. Radiographic and clinical features such as large entry tears and false lumen pressurization indicate patients are at higher risk of experiencing adverse aorta-related events. Upfront thoracic endovascular aortic repair may reduce late rupture risk, but carries procedural risks that complicate timing and trial inclusion. uTBAD is a dynamic disease that may progress to complicated TBAD during medical management. Improved risk stratification, monitoring, and timely rescue interventions are essential. Dedicated study of early medical failure and pragmatic trial designs are needed to refine treatment paradigms and optimize outcomes.